Investors May Lead Securities Fraud Lawsuit Against Capricor Therapeutics
Rosen Law Firm has initiated a class action lawsuit on behalf of purchasers of Capricor Therapeutics securities. The suit alleges securities fraud occurred between late 2025 and summer 2026.
New York, Aug. 13, 2026 – Rosen Law Firm, a global investor rights law firm, has announced the commencement of a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities. The lawsuit covers the period between December 17, 2025, and July 26, 2026, inclusive.
According to Rosen Law Firm, Capricor Therapeutics may have made materially misleading statements regarding the clinical results of the company's Hope treatment, an allogeneic regenerative medicine derived from fetal cardiomyocytes. The allegations suggest the company failed to adequately disclose potential safety issues with the Hope treatment or that the treatment did not meet its stated objectives.
Investors who purchased Capricor Therapeutics securities during the specified period and incurred losses are encouraged to contact Rosen Law Firm. The firm is seeking lead plaintiffs to pursue the class action to recover damages for investors.
The company's stock performance is likely to be scrutinized in light of these allegations. Investors will be closely examining any public statements made by Capricor Therapeutics and the potential implications of the ongoing legal proceedings.